AtaiBeckley Inc.

424B3 priced

352,693,006 shares

AtaiBeckley Inc. (formerly atai Life Sciences N.V.) is advancing its acquisition of Beckley Psytech Limited and a redomiciliation transaction to Delaware. The current 424B3 filing updates the prospectus with amendments to the Share Purchase Agreement (SPA), including a reduction in shares issued to Beckley Psytech shareholders, adjustments to leakage provisions, and revised definitions for 'Buyer Share Price' and 'VWAP.' The filing also outlines the conversion of atai LuxCo into a Delaware corporation, pending shareholder approvals. The company seeks Nasdaq approval to list shares under the same symbol 'ATAI' post-redomiciliation.

424B3 priced

352,693,006 shares

AtaiBeckley Inc. is seeking shareholder approval for a proposed acquisition of Beckley Psytech Limited and a redomiciliation transaction. The transaction involves merging Atai Life Sciences N.V. into Atai Life Sciences Luxembourg S.A. (atai LuxCo), followed by converting atai LuxCo into a Delaware corporation. Shareholders must approve the acquisition, share issuance (105,044,902 ordinary shares), and redomiciliation steps. If the acquisition is completed, atai LuxCo will rebrand as 'Atai Beckley Inc.'; otherwise, it will become 'Atai Life Sciences Inc.'

EFFECT effective

Atai Life Sciences Luxembourg S.A. filed a Notice of Effectiveness for its S-4 registration statement, confirming the completion of a redomiciliation process. The company plans to merge with and into Atai Life Sciences Luxembourg S.A. (LuxCo Merger) and convert to a Delaware corporation (Delaware Conversion), resulting in a name change to 'Atai Beckley Inc.' upon completion of the acquisition of Beckley Psytech Limited. Shareholder approvals are required for the acquisition, share issuance, and corporate restructuring, with the redomiciliation contingent on these approvals.

S-4 filed

352,693,006 shares

AtaiBeckley Inc. (formerly Atai Life Sciences N.V.) is undergoing a redomiciliation process to convert from a Luxembourg entity into a Delaware corporation, contingent on shareholder approvals. The process involves merging with Atai Life Sciences Luxembourg S.A. (atai LuxCo) and subsequently converting to a Delaware corporation, with the name changing to 'Atai Beckley Inc.' if the acquisition of Beckley Psytech Limited is completed. The filing includes a proxy statement for shareholder approvals of the acquisition and redomiciliation, alongside a prospectus for the new Delaware entity. The acquisition of Beckley Psytech involves issuing 105,044,902 ordinary shares, requiring shareholder consent under Nasdaq rules.

DRS filed

AtaiBeckley Inc. is undergoing a redomiciliation process, transitioning from a Luxembourg public limited liability company (atai LuxCo) to a Delaware corporation. This involves a merger with atai Life Sciences N.V. (the LuxCo Merger) followed by the Delaware Conversion. The filing also relates to the acquisition of Beckley Psytech Limited, which requires shareholder approval. The registration statement includes a prospectus for shares issued post-redomiciliation and a proxy statement for shareholder resolutions. The transaction aims to simplify corporate structure and enhance shareholder value.